'Clinical and Economical Considerations For IV Push Drug Delivery' by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Profes...(an MBA fromCalifornia State University S...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
'Clinical and Economical Considerations For IV Push Drug Delivery' by Industry Expert Richard Rosenfeld Is Now Accessible on Expert411.com for Media and Professional Use
Date:12/27/2007
an MBA from California State University, San Marcos.
About Baxa Corporation
Baxa, a customer-focused medical device company, provides innovative,
solution-based technologies for fluid handling and delivery. Its systems
and devices promote the safe and efficient preparation, handling,
packaging, and administration of fluid medications. Key products include
the PadLock(R) Set Saver, Rapid-Fill(TM) Automated Syringe Fillers,
Exacta-Med(R) Oral Dispensers, MicroFuse(R) Syringe Infusers, Repeater(TM)
Pharmacy Pumps, and Exacta-Mix(TM) and MicroMacro(TM) Multi-Source
Automated Compounders; used worldwide in hospitals and healthcare
facilities. Privately held, Baxa Corporation has subsidiaries and sales
offices in Canada and the United Kingdom; direct representation in Austria,
Belgium, Finland, France, Germany, Luxembourg, The Netherlands and
Switzerland; and distribution partners worldwide. Further information is
available at http://www.baxa.com.
Contacts:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: marian.robinson@baxa.com
Maggie Chamberlin Holben, APR, Absolutely Public Relations
303.984.9801, 303.669.3558
Email: maggie@absolutelypr.com
'/>"/>
| SOURCE Baxa Corporation Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
6. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Post Your Comments:
Breaking Biology Technology:AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 2Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. 3WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6
[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia[0] Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. [0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening[0] RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE)
Other Biology Technology:Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 2Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 3Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 4Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs 5Kingfisher Healthcare Receives European CE Mark for Next Generation Wound Healing Device 2Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification 2
Breaking Biology News(10 mins):Plate-eating good: Université de Montréal professor designs edible tableware 2Spices halt growth of breast stem cells, U-M study finds 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 2$2.4 million stimulus fuels effort to regenerate injured spinal cords 3$2.4 million stimulus fuels effort to regenerate injured spinal cords 4Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line 9403 1Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line 9403 2Fujitsu Expands Support for Ethernet Networks With New Additions to XG Switch Product Line 9403 3Sex in the Caribbean 3A Environmental change drives evolutionary change eventually 9402 1Sex in the Caribbean 3A Environmental change drives evolutionary change eventually 9402 2Breaking barriers with nanoscale lasers 13239 1Breaking barriers with nanoscale lasers 13239 2Breaking barriers with nanoscale lasers 13239 3Breaking barriers with nanoscale lasers 13239 4
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |